IL313067A - Methods of treating neurological disorders - Google Patents
Methods of treating neurological disordersInfo
- Publication number
- IL313067A IL313067A IL313067A IL31306724A IL313067A IL 313067 A IL313067 A IL 313067A IL 313067 A IL313067 A IL 313067A IL 31306724 A IL31306724 A IL 31306724A IL 313067 A IL313067 A IL 313067A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- neurological disorders
- treating neurological
- fesoterodine
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163283140P | 2021-11-24 | 2021-11-24 | |
| US202263416745P | 2022-10-17 | 2022-10-17 | |
| PCT/US2022/080429 WO2023097276A1 (en) | 2021-11-24 | 2022-11-23 | Methods of treating neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL313067A true IL313067A (en) | 2024-07-01 |
Family
ID=86540399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313067A IL313067A (en) | 2021-11-24 | 2022-11-23 | Methods of treating neurological disorders |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250032460A1 (https=) |
| EP (1) | EP4436564A4 (https=) |
| JP (1) | JP2024541770A (https=) |
| KR (1) | KR20240110642A (https=) |
| AU (1) | AU2022396530A1 (https=) |
| CA (1) | CA3239067A1 (https=) |
| IL (1) | IL313067A (https=) |
| MX (1) | MX2024006371A (https=) |
| WO (1) | WO2023097276A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3061821T (pt) * | 2009-07-22 | 2019-09-05 | PureTech Health LLC | Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos |
| US8853219B2 (en) * | 2010-01-11 | 2014-10-07 | Neurosolis, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| WO2012033956A1 (en) * | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Cognition enhancing compounds and compositions, methods of making, and methods of treating |
| US9012489B2 (en) * | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| CA2978214A1 (en) * | 2015-03-06 | 2016-09-15 | Chase Pharmaceuticals Corporation | Peripheral-anticholinergic muscarinic agonist combination |
-
2022
- 2022-11-23 MX MX2024006371A patent/MX2024006371A/es unknown
- 2022-11-23 AU AU2022396530A patent/AU2022396530A1/en active Pending
- 2022-11-23 IL IL313067A patent/IL313067A/en unknown
- 2022-11-23 JP JP2024531094A patent/JP2024541770A/ja active Pending
- 2022-11-23 US US18/712,916 patent/US20250032460A1/en active Pending
- 2022-11-23 CA CA3239067A patent/CA3239067A1/en active Pending
- 2022-11-23 EP EP22899553.6A patent/EP4436564A4/en active Pending
- 2022-11-23 WO PCT/US2022/080429 patent/WO2023097276A1/en not_active Ceased
- 2022-11-23 KR KR1020247020828A patent/KR20240110642A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3239067A1 (en) | 2023-06-01 |
| US20250032460A1 (en) | 2025-01-30 |
| JP2024541770A (ja) | 2024-11-12 |
| EP4436564A4 (en) | 2025-10-22 |
| EP4436564A1 (en) | 2024-10-02 |
| MX2024006371A (es) | 2024-07-15 |
| AU2022396530A1 (en) | 2024-06-13 |
| KR20240110642A (ko) | 2024-07-15 |
| WO2023097276A1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551792A1 (en) | Bi-ligand drug conjugate and use thereof | |
| EP2255798A3 (en) | Sphingosine-1-phosphate receptor agonists for use in the treatment of optic neuritis | |
| EP4464378A3 (en) | Leucine, acetyl leucine, and related analogs for treating disease | |
| WO2009067397A3 (en) | Treatment for solid tumors | |
| IL300151A (en) | Combinations for cancer treatment | |
| WO2006037031A3 (en) | Formulations and methods for treatment of inflammatory diseases | |
| EP1933833B8 (en) | Therapy for the treatment of overactive bladder | |
| WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
| EP1251126A3 (en) | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| NO994165L (no) | Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet | |
| WO2007022408A3 (en) | Combination methods of saha and targretin for treating cancer | |
| WO2023141334A3 (en) | Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders | |
| EP1902715A3 (en) | Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function | |
| EP4585269A3 (en) | Methods for cancer therapy | |
| IL273929B1 (en) | Therapeutic agents for neurodegenerative diseases | |
| WO2006098979A3 (en) | Aminopterin dosage forms and methods for inflammatory disorders | |
| WO2020101790A3 (en) | Methods of using a phenoxypropylamine compound to treat pain | |
| IL313067A (en) | Methods of treating neurological disorders | |
| EA202193211A1 (ru) | Лечение синуклеопатий | |
| CA2519789A1 (en) | Aplidine for multiple myeloma treatment | |
| PH12021552681A1 (en) | Therapeutic drug for dyskinesia | |
| WO2023019095A3 (en) | Momelotinib combination therapy | |
| WO2024145288A3 (en) | Methods of administering r-ketamine | |
| CA3199014A1 (en) | Combination therapy for the treatment of a liver disease |